CTLA4 and hereditary sensory and autonomic neuropathy: A previous study reported the median time to the onset of CIP was typically approximately 2.8 months (the overall range spanned from 9 days to 19.2 months) from patients who received anti-PD-1/PD-L1 monotherapy or in combination with anti-CTLA4 therapy were identified at two institutions (Memorial Sloan Kettering Cancer Center: advanced solid cancers, 2009 to 2014, and Melanoma Institute of Australia: melanomas only, 2013–2015) (Naidoo et al., 2017).